GlassScriptPhysician profile
Anupreet Kaur
NPI 1417244393
$2,338.50
in general payments reported to CMS, 2019-2025
32 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $111 · 2021: $225 · 2022: $618 · 2023: $514 · 2024: $369 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $388.22 | 2021-2025 | |
| Novo Nordisk INC | $387.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $210.53 | 2019-2024 | Gardasil 9, Vaxneuvance, M-M-R II |
| Pfizer INC. | $114.95 | 2022-2024 | |
| Amgen INC. | $114.13 | 2019-2023 | Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $113.18 | 2019-2024 | Airsupra, Breztri |
| Abbott Laboratories | $103.19 | 2021-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $92.59 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $84.69 | 2022-2024 | Jardiance, Mounjaro, Emgality |
| Novartis Pharmaceuticals Corporation | $83.31 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $64.33 | 2022 | |
| Janssen Pharmaceuticals, INC | $57.47 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.68 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $53.67 | 2022-2025 | Veozah |
| Dexcom, INC. | $45.72 | 2022-2023 | Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $44.45 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.91 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.51 | 2019-2022 | |
| Allergan, INC. | $32.89 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $26.67 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $25.57 | 2019-2020 | |
| Corcept Therapeutics | $19.28 | 2024 | Korlym |
| Cardiovascular Systems INC. | $18.62 | 2020 | |
| Medtronic, INC. | $17.73 | 2022 | |
| Genentech USA, INC. | $16.98 | 2019 | |
| Vital Connect, INC | $15.27 | 2024 | Vitalpatch Rtm |
| Lucid Diagnostics INC. | $13.47 | 2022 | |
| Daiichi Sankyo INC. | $13.27 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.62 | 2022 | |
| Gilead Sciences, INC. | $12.48 | 2019 | |
| Medtronic Vascular, INC. | $12.00 | 2019 | |
| Kci USA, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anupreet Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.